LG
Longeveron Inc.
LGVN · NASDAQ
$2.44 +3.83% (+$0.09)
1M -63.31%
Market Cap $7.43M
P/E Ratio -
Div. Yield -
ROE 223.19%
Bulios Fair Price
$1.77
27.5% downside
Current Price
$2.44
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LGVN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
61 /100
Fair P/S 6.26x
P/B 0.71x
P/E N/A
Growth
13 /100
Declining Rev. growth 0.63%
Book val. growth 34.83%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 69.76%
Net margin 1,977.59%
Op. margin 1,992.84%
Quality
1 /100
Poor ROIC 201.13%
ROE 223.19%
ROA 151.57%
Debt
100 /100
Low Debt/Equity 0.06x
Current ratio 2.63x
Int. coverage N/A
Stability
20 /100
Unstable Beta -0.26x
Rev. volatility 163.61%
EPS volatility 61.64%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LGVN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen H. Willard
Employees
38
Headquarters
Miami
Upcoming events
03 NOV
Earnings
Upcoming earnings report